Evolus Inc (EOLS) Director Simone Blank Purchases 628,536 Shares

Share on StockTwits

Evolus Inc (NASDAQ:EOLS) Director Simone Blank purchased 628,536 shares of the company’s stock in a transaction on Monday, May 20th. The shares were purchased at an average cost of $19.25 per share, for a total transaction of $12,099,318.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ EOLS traded down $0.01 on Wednesday, hitting $17.52. 573,342 shares of the stock were exchanged, compared to its average volume of 1,060,925. The company has a current ratio of 14.80, a quick ratio of 14.52 and a debt-to-equity ratio of 0.96. Evolus Inc has a 52 week low of $10.22 and a 52 week high of $39.50. The firm has a market capitalization of $478.87 million, a P/E ratio of -11.16 and a beta of 5.01.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.11). On average, research analysts anticipate that Evolus Inc will post -3.06 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC bought a new stake in Evolus during the first quarter worth about $115,000. Metropolitan Life Insurance Co NY bought a new stake in Evolus during the first quarter worth about $83,000. Perceptive Advisors LLC bought a new stake in Evolus during the first quarter worth about $344,000. Morgan Stanley lifted its position in Evolus by 239.8% during the first quarter. Morgan Stanley now owns 201,708 shares of the company’s stock worth $4,552,000 after purchasing an additional 142,351 shares during the period. Finally, SEI Investments Co bought a new stake in Evolus during the first quarter worth about $416,000. Hedge funds and other institutional investors own 19.33% of the company’s stock.

EOLS has been the topic of several analyst reports. Zacks Investment Research lowered shares of Evolus from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Evolus in a research report on Tuesday, April 30th. Stifel Nicolaus initiated coverage on shares of Evolus in a research report on Monday, January 28th. They set a “buy” rating and a $27.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Evolus in a research report on Thursday, April 4th. Finally, SunTrust Banks initiated coverage on shares of Evolus in a research report on Wednesday, March 20th. They set a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Evolus has an average rating of “Buy” and a consensus target price of $31.00.

TRADEMARK VIOLATION NOTICE: “Evolus Inc (EOLS) Director Simone Blank Purchases 628,536 Shares” was first posted by Highlight Press and is owned by of Highlight Press. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://highlightpress.com/2019/05/22/evolus-inc-eols-director-simone-blank-purchases-628536-shares.html.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Recommended Story: Stop Order

Insider Buying and Selling by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.